8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
May 7, 2026·SEC
Gyre Therapeutics, Inc.(GYRE)Earnings, Financials & Key Ratios
GYRE•NASDAQ
$7.01
311.6× P/E·Price updated Jul 7, 2026
AboutGyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.Show more
- Revenue$117M+10.2%
- EBITDA$14M-21.1%
- Net Income$5M-58.4%
- EPS (Diluted)0.02-55.0%
- Gross Margin95.35%-1.0%
- EBITDA Margin12.02%-28.4%
- Operating Margin9.86%-35.5%
- Net Margin4.31%-62.3%
- ROE4.18%-80.6%
GYRE Price & Volume
Gyre Therapeutics, Inc. (GYRE) stock price & volume — 10-year historical chart
Loading chart...
Volatile Revenue Growth Masks Structural Margin Inefficiency
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Strained
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Geopolitical and regulatory concentration
Key Thesis Takeaways
- Gyre Therapeutics presents a complex investment profile characterized by high-margin commercial drug sales in China, which are currently offset by erratic operating performance and significant geographic concentration risks.
- While the company has successfully stabilized its balance sheet from a $15.8M equity deficit in 2023Q4 to $101.3M in 2026Q1, the lack of consistent operating leverage remains a primary concern for long-term scalability.
- Investors should monitor the company's ability to translate its 94.6% gross margin into sustainable net profitability as it navigates the regulatory and competitive landscape of its fibrosis asset pipeline.
Verdict Logic
while the balance sheet has stabilized with $37.5M in cash as of 2026Q1, the company's inability to maintain consistent operating profitability—evidenced by a $9.4M operating loss in the most recent quarter—warrants a cautious wait-and-see approach.
GYRE Growth Metrics
Gyre Therapeutics, Inc. (GYRE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years52.18%
5 Years40.96%
3 Years4.46%
TTM16.3%
Profit CAGR
10 Years-
5 Years-
3 Years29.74%
TTM-186.71%
EPS CAGR
10 Years-
5 Years-
3 Years-9.14%
TTM-8.89%
Return on Capital
10 Years-54.14%
5 Years-35.93%
3 Years-18.18%
Last Year9.06%
GYRE Recent Earnings
Gyre Therapeutics, Inc. (GYRE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (22%)●Beat Revenue 2/12 qtrs (29%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.05+16.7%
$0.06
Rev
$23M-28.8%
$32M
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.04-29.4%
$0.06
Rev
$37M+5.0%
$35M
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$0.06+20.0%
$0.05
Rev
$31M-15.8%
$36M
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.02-33.3%
$0.03
Rev
$27M-22.0%
$34M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.05vs $0.06+16.7% | $23Mvs $32M-28.8% |
| Q2 2026 | Mar 12, 2026 | $0.04vs $0.06-29.4% | $37Mvs $35M+5.0% |
| Q4 2025 | Nov 7, 2025 | $0.06vs $0.05+20.0% | $31Mvs $36M-15.8% |
| Q3 2025 | Aug 11, 2025 | $0.02vs $0.03-33.3% | $27Mvs $34M-22.0% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Gyre Therapeutics, Inc. (GYRE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.01 | $679.93M | 311.56 | 10.24% | 4.31% | 4.18% | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — | |
| $5.38 | $1.32B | -20.69 | 22.09% | -13.58% | -38.11% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — |
Compare GYRE vs Peers
Gyre Therapeutics, Inc. (GYRE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GYRE SEC Filings & Documents
Gyre Therapeutics, Inc. (GYRE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when GYRE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GYRE Frequently Asked Questions
Gyre Therapeutics, Inc. (GYRE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Gyre Therapeutics, Inc.'s revenue?
Gyre Therapeutics, Inc. (GYRE) reported $117.0M in revenue for fiscal year 2025. This represents a 3031% increase from $3.7M in 2004.
How fast is Gyre Therapeutics, Inc. growing?
Gyre Therapeutics, Inc. (GYRE) grew revenue by 10.2% over the past year. This is steady growth.
Is GYRE profitable?
Gyre Therapeutics, Inc. (GYRE) reported a net loss of $6.3M for fiscal year 2025.
Dividend & Returns
What is GYRE's return on equity?
Gyre Therapeutics, Inc. (GYRE) has a return on equity (ROE) of 4.2%. This is below average, suggesting room for improvement.
What is Gyre Therapeutics, Inc.'s free cash flow?
Gyre Therapeutics, Inc. (GYRE) generated $3.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.